Hemolysis and methemoglobinemia secondary to rasburicase administration. - Wikidata - awgldk - TriplyDB

Hemolysis and methemoglobinemia secondary to rasburicase administration.

Hemolysis and methemoglobinemia secondary to rasburicase administration.

http://www.wikidata.org/entity/Q46735562

about

Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout Tumor lysis syndrome: new challenges and recent advances.A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin's Lymphoma.PharmGKB summary: very important pharmacogene information for G6PD.Clarifying the role of rasburicase in tumor lysis syndrome.Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.Personalized medicine and the clinical laboratory.Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).Synergistic Degradation of a Hyperuricemia-Causing Metabolite Using One-Pot Enzyme-Nanozyme Cascade Reactions New advances in the treatment of gout: review of pegloticase The clinical management of tumour lysis syndrome in haematological malignancies.Methemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature review.Rasburicase for the treatment of tumor lysis in hematological malignancies.Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.Enzymes approved for human therapy: indications, mechanisms and adverse effects.Advances in the Pharmacogenomics of Adverse Drug Reactions.PharmGKB summary: methylene blue pathway.Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia.Mortality following rasburicase-induced methemoglobinemia.Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.[Association of methemoglobinemia and glucose-6-phosphate dehydrogenase deficiency in malaria patients treated with primaquine].Tumor Lysis Syndrome in Patients with Hematological Malignancies.Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia.

P2860

Q24673444-D679255D-8289-4194-B3CC-C51E65A6EF4A Q33595615-ABCF498F-3471-4FAA-B30B-D0ADF5864C7D Q33947841-1A3E3228-979C-47E2-9A24-11777CFBF759 Q36036576-CB3C3B7B-991F-4AE7-BCBE-975347097581 Q36055205-4F961985-5E43-4244-B04E-9D90234959D5 Q36693863-3DD8626E-9B5D-483D-8565-ABB8C9304908 Q36797533-4FE22533-02A8-4917-B563-7A4E913605D5 Q36916966-8D88C907-F208-4FF0-853D-3430BA4BF4DB Q37586944-BB661857-9D70-4848-9453-E79A34FDE79F Q37695306-54914694-1E6B-4BCB-9348-8AB03B6696E1 Q37815379-BE5F1B17-0E74-4F95-8A4D-291AFF2F3BD4 Q37873541-813BAF27-8D3A-4D6F-BE40-9A845009287F Q37970663-B2C20C10-F2DC-4836-8B19-60BC4E93E2CC Q37978342-17B44BDF-A21C-4DAE-A8F1-D6AC8B62E51C Q38217626-0981121E-4633-4ED6-9B21-02626F6E31F3 Q38219092-BA7E8E35-2DC4-4FFB-9A21-103B6E0358DB Q38342838-6723BCB2-84DE-49E0-9568-471A1DEBA331 Q38663764-B1235877-24B6-42C1-B315-BB1D4E406E15 Q41890556-CC3C011B-4196-4E20-A446-92A927C9AD73 Q43198061-9FAD8E34-9A2F-4D46-B2AC-DDDBB9C31049 Q45062960-1E80A5E6-1146-47FB-BF72-2EF5407B976A Q46012059-AE7D5DB1-5DA7-4E27-AFC7-D183165451A2 Q46907919-DFAA725B-AB8E-41E5-9492-7C304146B943 Q46949121-DC789279-5CE6-4E76-92EF-8C1BBAFDA2E2 Q47135590-D3166667-0A60-4205-A505-682A4639CE50 Q49070468-D5F4F9B1-BFC2-4905-BADA-3D2FE3BFBECF

P2860

Hemolysis and methemoglobinemia secondary to rasburicase administration.

http://www.wikidata.org/entity/Q46735562

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Hemolysis and methemoglobinemia secondary to rasburicase administration.

@en

Hemolysis and methemoglobinemia secondary to rasburicase administration.

@nl

type

label

Hemolysis and methemoglobinemia secondary to rasburicase administration.

@en

Hemolysis and methemoglobinemia secondary to rasburicase administration.

@nl

prefLabel

Hemolysis and methemoglobinemia secondary to rasburicase administration.

@en

Hemolysis and methemoglobinemia secondary to rasburicase administration.

@nl

P1433

Q46735562-2D3B3C40-6CF8-485F-BBC3-71155630C4E0

P1476

Q46735562-7DC4177C-A379-497A-AA70-13D1A90C10B3

P2093

Q46735562-2525E4D1-8D42-4987-BE80-9D3170F07DB9

Q46735562-40B3E07D-C39E-4AA7-9641-49118E3B57AE

P2860

Q46735562-198D6670-4654-41F3-B69D-00AFB10BA737

Q46735562-3CD9BBE6-DD30-478A-9648-9CCE5DB70B95

Q46735562-6752D565-5B10-4E4D-A6B0-7565F5C484DD

Q46735562-6A87A86E-DBCD-42C2-8730-56D5CE30DA77

Q46735562-89832AEF-26D8-4E73-92E0-D60D89F76964

Q46735562-9C056F57-0FDB-4258-B1DA-3D846D8D0906

Q46735562-CDD266FE-A477-46AB-93BD-7F8C170DC9C6

Q46735562-EDC9A71B-5229-4A74-B75C-84D504F5FFE4

Q46735562-F48180DD-0209-4C5A-9F99-9ACA3840973E

Q46735562-FB7A1048-BD67-4617-83F7-9768325636E7

P304

Q46735562-C791E296-8DC5-4BA5-BE76-EDA5601E202F

P31

Q46735562-5D3B21B8-2A81-4FF3-833E-D71BC1E581D5

P356

Q46735562-14FDE086-4993-4C32-A86C-2BE4CD2EBD4B

P407

Q46735562-64A862FE-575B-4B73-8977-54FA7794263C

P433

Q46735562-231D71EA-507B-4A19-8F56-42A9F173AA1B

P478

Q46735562-15BBA022-C9AF-467C-BE48-9FEE8180E420

P577

Q46735562-86974E3D-C805-4196-835E-4F637347C9CC

P698

Q46735562-2B979B67-9971-4B8E-A5F1-1C926CBA7CC6

P356

P1433

Annals of Pharmacotherapy

P1476

Hemolysis and methemoglobinemia secondary to rasburicase administration.

@en

P2093

James A Kruse

http://www.w3.org/2001/XMLSchema#string

Linda A Browning

http://www.w3.org/2001/XMLSchema#string

P2860

A method for estimating the probability of adverse drug reactions

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.

Methemoglobinemia: etiology, pharmacology, and clinical management.

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Tria

Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.

Rasburicase for the treatment and prevention of hyperuricemia.

Management of acute and chronic gouty arthritis: present state-of-the-art.

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial.

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.

P304

1932-1935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1G272

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16204390

http://www.w3.org/2001/XMLSchema#string